SB 1581 - This act establishes the "Veterans Mental Health Innovation Act". Under this act, the Department of Health and Senior Services shall, subject to appropriation, award grants to conduct certified clinical drug development trials overseen by the U.S. Food and Drug Administration (FDA) on the use of ibogaine for the treatment of opioid use disorder, co-occurring substance use disorder, or any other neurological or mental health condition for which ibogaine demonstrates efficacy. Grantees shall meet the eligibility requirements set forth in the act, including having signed an agreement with a consortium established by another state that has submitted specified applications and requests with the FDA. This act creates the "Ibogaine Study Fund" in the state treasury for the disbursement of grants under this act. Selected grant applicants shall submit quarterly reports to the Department and the Department shall submit an annual report to the General Assembly on the progress of the trials. This act also creates the "Ibogaine Intellectual Property Fund" for all revenue attributable to all intellectual property rights and other commercial rights that may arise from drug development clinical trials conducted by a multistate consortium under this act during the period for which the trials are funded and any following period of commercialization. The moneys in the fund shall be used solely for programs that assist veterans or other at-risk populations in this state. If ibogaine is approved by the FDA to treat a medical condition, only a licensed physician shall prescribe it for a patient and a licensed physician shall supervise its administration at a hospital or other licensed health care facility. The Department shall begin accepting grant applications before November 1, 2026, but may delay implementation of some or all of the provisions of this act if the Department determines that a waiver or authorization from a federal agency is first necessary. This act is identical to HB 2961 (2026). SARAH HASKINS

2026 Regular Session Introduced by Jason Bean

Missouri bill authorizes ibogaine clinical trials for veterans with PTSD and addiction, expanding access to federally-restricted but promising psychedelic therapy research.

Voted Do Pass S Veterans and Military Affairs Committee

Legislative bill overview

SB 1581 would establish a framework in Missouri to research and potentially permit ibogaine treatment for veterans with mental health conditions, particularly PTSD and substance use disorders. Ibogaine is a psychoactive compound derived from an African plant that has shown promise in clinical research but remains a Schedule I controlled substance federally. The bill would create pathways for clinical trials and supervised therapeutic use within the state.

Why is this important

Veterans face disproportionately high rates of PTSD, depression, and suicide, with limited treatment options proving effective for all patients. Ibogaine has demonstrated potential in preliminary studies for treating trauma and addiction, but federal restrictions have severely limited research in the U.S. This bill addresses a gap between emerging therapeutic possibilities and current legal barriers that prevent exploration of alternative treatments for a vulnerable population.

Potential points of contention

Federal-state conflict: Ibogaine remains Schedule I federally, creating legal tension between state authorization and federal drug law; unclear how this would be resolved in practice

Safety and efficacy concerns: Ibogaine carries documented cardiovascular risks and limited long-term safety data in human trials; establishing adequate medical oversight standards would be contentious

Research ethics and access: Questions about who qualifies, whether this becomes accessible treatment or experimental program for some veterans, and ensuring rigorous clinical standards rather than premature commercialization